Haemonetics (NYSE:HAE) said the American Red Cross went with 1 of its rivals for some components of the whole blood collection kits the relief agency uses, meaning a $25 million hit to Haemonetics’ top line.
Haemonetics
Haemonetics’ streamlining efforts boost Q3 profits by 64%
Massachusetts medical device maker Haemonetics (NYSE:HAE) this week released its 3rd-quarter earnings report, posting a major boost in profits that the company attributed to "productivity programs yielding cost efficiencies."
GPOs: Haemonetics inks supply deal with HemeXcel
Haemonetics (NYSE:HAE) signed a 2-year exclusive supply deal with HemeXcel Purchasing Alliance LLC, providing blood collection devices to group purchasing organization HemeXcel’s 5 blood centers.
Orthofix chairman Gero steps down | Personnel Moves
Listen to Haemonetics Q2 2014 earnings call
Haemonetics’ Q2 profits surge, lowers sales outlook
Haemonetics (NYSE:HAE) said its fiscal 2nd-quarter profits surged more than 150%, but lowered its sales outlook for the rest of fiscal 2014 on its expectation that blood transfusion rates will continue to slow down.
Haemonetics swings to Q1 red, lowers full-year guidance; Wall Street flees
Haemonetics Corp. (NYSE:HAE) took a Wall Street dip after posting a hard swing to the red and adjusted per-share earnings just shy of analysts’ expectations.
MassDevice.com +3 | The top 3 med-tech stories for June 20, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Haemonetics closes its doors in Mass., builds in Malaysia and Mexico
Haemonetics (NYSE:HAE) said it plans to hire Sanmina Corp. (NSDQ:SANM) to take over manufacturing from its plant in Braintree, Mass., and will expand in Mexico and Asia.
Haemonetics plans to cut 320 jobs, move manufacturing to Mexico, Asia
Haemonetics (NYSE:HAE) said it plans to shutter manufacturing operations in its Massachusetts home base and shift them to Mexico and Asia, reportedly cutting 320 jobs in the process.
Haemonetics dives despite Wall Street-beating Q3 numbers
Haemonetics (NYSE:HAE) shares are down some 9% today after the blood management company lowered its sales outlook for the rest of fiscal 2013, despite posting Wall Street-beating earnings per share for the 3 months ended Dec. 29, 2012.
Braintree, Mass.-based Haemonetics reported Q3 profits of $9.9 million, or 19¢ per share, on sales of $247.4 million. That’s a 45.7% profit slide and a 29.4% sales increase.